IBTK and mantle cell lymphoma: We have previously shown that BTKi have a unique molecular mechanism besides directly reducing MCL growth: by inhibiting the integrin-mediated adhesion of MCL cells to the lymphoid microenvironment the malignant cells are mobilized into the peripheral blood, which deprives the MCL cells from critical growth and survival factors provided in the lymphoid organs and bone marrow [2–5].